Company intelligence / Profile preview
AltruBio Inc.
San Francisco, California, United Statesaltrubio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
AltruBio's lead candidate ALTB-268 is currently in Phase 2a clinical trials for ulcerative colitis with primary endpoint readout expected in 1H 2025. The company has completed a Phase 1 study of ALTB-268 demonstrating safety and tolerability in healthy volunteers with no serious adverse events. Their first-generation molecule, ALTB-168, has shown proof of mechanism in four autoimmune and inflammatory diseases, including ulcerative colitis, psoriatic arthritis, psoriasis, and steroid refractory acute graft-versus-host disease (SR-aGVHD).
- Therapeutic areas
- GastroenterologyRheumatologyImmunologyDermatologyHematologyOncology
- Modalities
- Monoclonal antibodiesImmune checkpoint enhancers (ICE)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on AltruBio Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AltruBio Inc..